IMPEL PHARMACEUTICALS INC (IMPL) Stock Price, Quote, News and Overview
NASDAQ:IMPL - Nasdaq - US45258K1097 - Common Stock - Currency: USD
IMPL Quote, Performance and Key Statistics
0.2411
-0.17 (-41.79%)
The current stock price of IMPL is 0.2411 USD. In the past month the price decreased by -32.08%. In the past year, price decreased by -93.3%.
IMPL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMPL
Company Profile
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
Company Info
IMPEL PHARMACEUTICALS INC
201 Elliott Ave. W, Suite 260
Seattle WASHINGTON US
CEO: Adrian Adams
Employees: 160
Company Website: https://impelpharma.com/
Phone: 12065681466
IMPEL PHARMACEUTICALS INC / IMPL FAQ
What is the stock price of IMPEL PHARMACEUTICALS INC today?
The current stock price of IMPL is 0.2411 USD. The price decreased by -41.79% in the last trading session.
What is the ticker symbol for IMPEL PHARMACEUTICALS INC stock?
The exchange symbol of IMPEL PHARMACEUTICALS INC is IMPL and it is listed on the Nasdaq exchange.
On which exchange is IMPL stock listed?
IMPL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMPEL PHARMACEUTICALS INC stock?
8 analysts have analysed IMPL and the average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411. Check the IMPEL PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMPEL PHARMACEUTICALS INC worth?
IMPEL PHARMACEUTICALS INC (IMPL) has a market capitalization of 5.76M USD. This makes IMPL a Nano Cap stock.
How many employees does IMPEL PHARMACEUTICALS INC have?
IMPEL PHARMACEUTICALS INC (IMPL) currently has 160 employees.
Is IMPEL PHARMACEUTICALS INC (IMPL) expected to grow?
The Revenue of IMPEL PHARMACEUTICALS INC (IMPL) is expected to grow by 128.2% in the next year. Check the estimates tab for more information on the IMPL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMPEL PHARMACEUTICALS INC (IMPL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMPL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMPL, evaluating the profitability, health, valuation and growth aspects
- IMPEL PHARMACEUTICALS INC (IMPL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMPEL PHARMACEUTICALS INC (IMPL) Sales and EPS estimates to see what analysts future expectations are.
- IMPEL PHARMACEUTICALS INC (IMPL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMPEL PHARMACEUTICALS INC (IMPL) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMPEL PHARMACEUTICALS INC (IMPL) Stock Chart to make your own analysis
- IMPEL PHARMACEUTICALS INC (IMPL) Latest news and press-releases to stay up to date.
Does IMPEL PHARMACEUTICALS INC (IMPL) stock pay dividends?
IMPL does not pay a dividend.
What is the Price/Earnings (PE) ratio of IMPEL PHARMACEUTICALS INC (IMPL)?
IMPEL PHARMACEUTICALS INC (IMPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.41).
IMPL Technical Analysis
IMPL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IMPL. IMPL may be in some trouble as it scores bad on both profitability and health.
IMPL Financial Highlights
Over the last trailing twelve months IMPL reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 3.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -204.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMPL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to IMPL. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 64.5% and a revenue growth 128.2% for IMPL